Kite Pharma (KITE): Zuma-1 Debate Not Significant - Jefferies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/27/2026
- Nasdaq futures outperform after Nvidia puts AI fears to rest
- Nvidia forecasts 70% sales growth next year, signals AI spending boom has years left to run
- Oil gains as traders weigh prospects of Hormuz reopening
- Meta to pay up to $16.68 billion in mass social media settlement
- Anthropic agrees to $45bn cloud computing deal with Nscale - report
- Nutanix (NTNX) Tops Q4 EPS by 11c, Beats in Revenue; Offers Q1 Revenue Guidance
- Boston Scientific discloses cybersecurity incident causing global disruption
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- Wall Street stocks end tad lower after hot inflation data ahead of Nvidia earnings
- FDA approves Revolution Medicines pancreatic cancer drug Rasonque
Juno Situation Has Little Impact on Kite Pharma's (KITE) Ongoing ZUMA1 Pivotal Trial - Stifel
November 23, 2016 10:33 AM ESTStifel analyst Thomas Shrader weighed in on Kite Pharma (NASDAQ: KITE) after rival Juno Therapeutics has again placed the ROCKET trial on clinical hold following patient deaths due to cerebral edema. The firm reiterated a Buy rating and price target of $74 on KITE, saying this reinforces Kite's R&D focus. They believe this situation has little impact on the ongoing ZUMA1 pivotal... More
